The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review
Pharmacoepidemiology · 27.06.2025 · 4 (3) · 14
DOI: 10.3390/pharma4030014 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmacoepidemiology, online erschienen am 27.06.2025. Verfasst von Jahnavi Udaikumar und 6 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly encompassed under nonalcoholic fatty liver disease (NAFLD), is a growing global health burden associated with progression to cirrhosis and hepatocellular carcinoma. Resmetirom, a thyroid hormone receptor-β (THR-β) agonist, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), have emerged as promising agents targeting distinct metabolic and inflammatory pathways. This systematic review compares the safety and efficacy of resmetirom and semaglutide in MASLD.
Methods
We conducted a comprehensive search of PubMed, Embase, and Google Scholar for randomized controlled trials and clinical studies published between January 2014 and April 2025, following PRISMA guidelines. Studies assessing the efficacy and safety of resmetirom and/or semaglutide in MASLD or NASH were included. Data extraction was performed by two independent reviewers, and a narrative synthesis was undertaken due to the heterogeneity in study design and outcome measures.
Results
Fourteen studies encompassing over 4500 patients were analyzed. Resmetirom demonstrated consistent reductions in hepatic fat (≥30% in >50% of patients) and improvements in fibrosis (≥1 stage in up to 26.4% of patients), as evidenced in the MAESTRO-NASH trial. Semaglutide achieved higher rates of NASH resolution (up to 62.9%) without worsening fibrosis, especially among patients with type 2 diabetes or obesity, although fibrosis improvement was less consistently observed. Resmetirom was well tolerated with low discontinuation rates, while semaglutide was associated with more frequent, yet manageable, gastrointestinal adverse events.
Conclusions
Both resmetirom and semaglutide show therapeutic potential for MASLD. Resmetirom offers more consistent antifibrotic effects, while semaglutide excels in NASH resolution and metabolic improvement. The absence of direct comparative trials underscores the need for future head-to-head studies to guide tailored treatment strategies in MASLD management.
Zitieren
APA
Udaikumar, J., Nimmagadda, R., Lella, V. V., Achuta, K. M., Kuppili, S., Avula, S. R., & Sarwar, R. (2025). The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review. Pharmacoepidemiology, 4(3), 14. https://doi.org/10.3390/pharma4030014
Vancouver
Udaikumar J, Nimmagadda R, Lella VV, Achuta KM, Kuppili S, Avula SR, et al. The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review. Pharmacoepidemiology. 2025;4(3):14. doi:10.3390/pharma4030014
BibTeX
@article{Udaikumar2025,
author = {Udaikumar, Jahnavi and Nimmagadda, Rithish and Lella, Vindhya Vasini and Achuta, Kesava Manikanta and Kuppili, Satwik and Avula, Suraj Reddy and Sarwar, Raiya},
title = {The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review},
journal = {Pharmacoepidemiology},
year = {2025},
volume = {4},
number = {3},
pages = {14},
doi = {10.3390/pharma4030014}
}
EUVIMED